Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. (1st January 2022)
- Record Type:
- Journal Article
- Title:
- Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. (1st January 2022)
- Main Title:
- Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression
- Authors:
- Wang, Tingting
Lin, Qingyu
Zhang, Yingying
Xu, Zhan
Shi, Dai
Cheng, Yuan
Fu, Zhequan
Tan, Hui
Cheng, Dengfeng
Shi, Hongcheng - Abstract:
- Graphical abstract: 18 F-labeled IDH1 mutation inhibitor [ 18 F]AG120 was successfully developed and evaluated, and exhibited specific targeting to IDH1 mutant tumor model with positron emission tomography imaging. Abstract: Mutations in isocitrate dehydrogenase 1 (IDH1) are commonly found in various human malignancies. Inhibitors of several mutant IDH1 enzymes have entered clinical trials as target therapeutic drugs for the treatment of patients with IDH1 mutations. Herein, we report the synthesis and evaluation of two 18 F-labeled tracers, [ 18 F]AG120 and [ 18 F]AG135 for imaging expression of mutated IDH1 in positron emission tomography (PET). [ 18 F]AG120 and [ 18 F]AG135 were synthesized in decay-corrected radiochemical yield of 1 % and 3 %, respectively, high molar activity (52–66 MBq/nmol and 216–339 MBq/nmol, respectively) and high radiochemical purity (>99%). Both tracers showed good in vitro stability, selective uptake into mutated IDH1-expressing cells and good pharmacokinetic profiles with low uptake in most organs/tissues. Furthermore, [ 18 F]AG120 micro-PET/CT imaging displayed significantly greater uptake in IDH1-mutant than in wild-type tumors, Relatively, uptake of [ 18 F]AG135 was observed neither in IDH1-mutant tumor xenografts nor in wild-type tumors. This study suggests that [ 18 F]AG120 is a promising radiotracer for PET imaging of IDH1 mutation, However, further optimization and investigation are necessary for [ 18 F]AG135 due to the limited uptake inGraphical abstract: 18 F-labeled IDH1 mutation inhibitor [ 18 F]AG120 was successfully developed and evaluated, and exhibited specific targeting to IDH1 mutant tumor model with positron emission tomography imaging. Abstract: Mutations in isocitrate dehydrogenase 1 (IDH1) are commonly found in various human malignancies. Inhibitors of several mutant IDH1 enzymes have entered clinical trials as target therapeutic drugs for the treatment of patients with IDH1 mutations. Herein, we report the synthesis and evaluation of two 18 F-labeled tracers, [ 18 F]AG120 and [ 18 F]AG135 for imaging expression of mutated IDH1 in positron emission tomography (PET). [ 18 F]AG120 and [ 18 F]AG135 were synthesized in decay-corrected radiochemical yield of 1 % and 3 %, respectively, high molar activity (52–66 MBq/nmol and 216–339 MBq/nmol, respectively) and high radiochemical purity (>99%). Both tracers showed good in vitro stability, selective uptake into mutated IDH1-expressing cells and good pharmacokinetic profiles with low uptake in most organs/tissues. Furthermore, [ 18 F]AG120 micro-PET/CT imaging displayed significantly greater uptake in IDH1-mutant than in wild-type tumors, Relatively, uptake of [ 18 F]AG135 was observed neither in IDH1-mutant tumor xenografts nor in wild-type tumors. This study suggests that [ 18 F]AG120 is a promising radiotracer for PET imaging of IDH1 mutation, However, further optimization and investigation are necessary for [ 18 F]AG135 due to the limited uptake in mutated IDH1-expressing tumors. … (more)
- Is Part Of:
- Bioorganic & medicinal chemistry. Volume 53(2022)
- Journal:
- Bioorganic & medicinal chemistry
- Issue:
- Volume 53(2022)
- Issue Display:
- Volume 53, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 53
- Issue:
- 2022
- Issue Sort Value:
- 2022-0053-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-01-01
- Subjects:
- 18F -- PET imaging -- Radiosynthesis -- IDH1 mutation -- IDH1 inhibitor
Bioorganic chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
Chemistry, Clinical -- Periodicals
Chemistry, Organic -- Periodicals
Chimie bio-organique -- Périodiques
Chimie pharmaceutique -- Périodiques
615.19 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09680896 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.bmc.2021.116525 ↗
- Languages:
- English
- ISSNs:
- 0968-0896
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.325000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20260.xml